Abstral® - treatment of breakthrough cancer pain
Abstral® is a rapidly disintegrating sublingual tablet for management of breakthrough cancer pain in patients already being treated with opioids. The product contains the pain-relieving substance fentanyl. Abstral® allows doses to be customized according to individual requirements, which is essential for achieving optimal pain relief.
|Indication||Breakthrough cancer pain|
|Market approvals||US, EU, RoW among others Japan, Australia, Saudi Arabia and South Korea|
|Commercial rights||RoW, Kyowa Kirin|
|Patent protection||On RoW markets until 2024. For the US and the EU the patents expired in September 2019.|
The product was initially approved for sales in Europe in 2008. Approval and launch in other major territories has followed, and Abstral® is currently available in key markets such as Japan, Australia and South-Korea. Globally, the market for Abstral® has continued to grow rapidly over the years.